MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, they show that catalytic mTOR inhibitors PI-103 and its derivative NVP-BEZ235 (which inhibit both mTORC1 and mTORC2 and have activity against all PI3K isoforms) induce autophagy and implied that mTOR inhibition could serve as an alternative therapeutic approach in TKI-resistant CML cells [229].